Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 8/20 | 0.37 |
| ▸ | CDK9 | P50750 | 8/20 | 0.37 |
| ▸ | WDR5 | P61964 | 8/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069896 | 1.00 | CCNT1 (0.37) | CCNT1CDK9WDR5MAPK1MAOA | |
| SCHEMBL4555118 | 0.90 | MAOA (0.39) | CCNT1CDK9WDR5MAPK1MAOA | |
| SCHEMBL9930041 | 0.89 | MAOB (0.47) | CCNT1CDK9WDR5MAPK1MAOA | |
| SCHEMBL9930385 | 0.88 | CCNT1 (0.36) | CCNT1CDK9WDR5MAPK1MAOA | |
| SCHEMBL9930158 | 0.88 | WDR5 (0.32) | WDR5MAOAMAOBCYP2C19 | |
| SCHEMBL14069349 | 0.88 | MAOA (0.39) | CCNT1CDK9WDR5MAPK1MAOA | |
| SCHEMBL9968668 | 0.88 | CCNT1 (0.40) | CCNT1CDK9WDR5MAOAMAOB | |
| SCHEMBL9929656 | 0.88 | MAOA (0.39) | CCNT1CDK9WDR5MAPK1MAOA | |
| SCHEMBL14069434 | 0.88 | CDK9 (0.36) | CCNT1CDK9WDR5MAPK1BTK | |
| SCHEMBL9930610 | 0.88 | CDK9 (0.36) | CCNT1CDK9WDR5MAPK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-9120747-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651896-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8586536-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | CCNT1 2199/4885CDK9 4145/4885WDR5 4437/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | CCNT1 2199/4885CDK9 4145/4885WDR5 4437/4885 |
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2199/4885CDK9 4145/4885WDR5 4437/4885 |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2199/4885CDK9 4145/4885WDR5 4437/4885 |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2199/4885CDK9 4145/4885WDR5 4437/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2166/4885CDK9 4217/4885WDR5 4487/4885 |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | CCNT1 775/4885CDK9 1980/4885WDR5 3083/4885 |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | CCNT1 2199/4885CDK9 4145/4885WDR5 4437/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | CCNT1 2280/4885CDK9 3847/4885WDR5 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.